Affymetrix Inc. intends to defend against all of Illumina’s patent infringement claims.
On May 4, 2009, the Company was named as a defendant in a complaint filed by plaintiff Illumina, Inc.…
Affymetrix Inc. continues to defend a patent infringement complaint by E8 Pharmaceuticals LLC and Massachusetts Institute of Technology in the U.S. District Court of Massachusetts.
On July 1, 2008, the Company…
Genzyme Corporation remains in dispute with Impax Laboratories, Inc. over U.S. Patent No. 5,667,775, which expires in 2014.
The Company received notice in 2009, from Impax that it had submitted to…
Affymetrix Inc.’s action against Enzo Life Sciences, Inc., a wholly-owned subsidiary of Enzo Biochem, Inc., for wrongful conduct related to its patent portfolio remains ongoing.
On Nov. 10, 2003, the Company…
Lupin Ltd. and Lupin Pharmaceuticals continue to challenge Genzyme Corporation’s U.S. Patent No. 5,667,775, which expires in 2014.
The Company received notice in 2009 from Lupin that it had submitted to…
Fresenius Medical Care Holdings, Inc.’s liability for infringing valid claims of Baxter International Inc.’s main patent affirmed in September 2009.
Since April 2003, Baxter has been pursuing a patent infringement action…
A trial on Baxter Healthcare Corporation’s patent infringement lawsuit against Fresenius Medical Care Holdings, Inc. and Fresenius USA, Inc., is anticipated in mid-2010.
On Oct. 16, 2006, Baxter Healthcare, a direct…
Merck & Co. Inc. and Schering-Plough Corporation continue to pursue a patent infringement lawsuit against generic pharmaceutical manufacturers who filed abbreviated new drug applications for generic ezetimibe (Zetia).
An abbreviated new…
Teva Pharmaceuticals Inc. has appealed the decision upholding the validity of Merck & Co. Inc.’s Singulair patent.
On Aug. 19, 2009, the U.S. District Court for the District of New Jersey…
Merck & Co. Inc. continues to evaluate the information provided with an Abbreviated New Drug Application notice to determine what action should be taken.
In January 2009, the Company received notice…